Featured Press Releases

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

Fresenius-Kabi_17122024

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

  • 17 Dec 2024

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is...

Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies

Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies

The American Kidney Fund

The American Kidney Fund's Rare Kidney Disease Advocacy Day on Capitol Hill aims to gather support for legislation to boost awareness and treatment of rare kidney diseases.

Medicines Discovery Catapult and Crown Bioscience form a global alliance for radiopharmaceutical innovation

Medicines Discovery Catapult and Crown Bioscience form a global alliance for radiopharmaceutical innovation

Beauty Crush Skincare Introduces a New Standard in Regenerative Biotech Skincare

Beauty Crush Skincare Introduces a New Standard in Regenerative Biotech Skincare

Industry Veteran Marie Emms Appointed President of Clinical Business at Spectrum Science

Industry Veteran Marie Emms Appointed President of Clinical Business at Spectrum Science

  • Spectrum Science
  • 08 Jul 2026
Cannabix Technologies and Omega Laboratories Announce a DOT-Like Breath-Based Drug Testing Panel for Recent-Use Detection

Cannabix Technologies and Omega Laboratories Announce a DOT-Like Breath-Based Drug Testing Panel for Recent-Use Detection

  • Omega Laboratories, Inc.
  • 08 Jul 2026
Organon to Present New Analysis of VTAMA® (tapinarof) Cream, 1%

Organon to Present New Analysis of VTAMA® (tapinarof) Cream, 1%

  • Organon
  • 07 Jul 2026
European Commission Approves AbbVie

European Commission Approves AbbVie's TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • AbbVie
  • 06 Jul 2026
Nnamdi Njoku Named President of Omnicell

Nnamdi Njoku Named President of Omnicell

  • Omnicell, Inc.
  • 01 Jul 2026
Eligible Medicare Beneficiaries Living with Obesity Can Now Access Wegovy® Through the Medicare GLP-1 Bridge

Eligible Medicare Beneficiaries Living with Obesity Can Now Access Wegovy® Through the Medicare GLP-1 Bridge

  • Novo Nordisk
  • 01 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.